Alto Neuroscience Inc ANRO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
-
Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer
-
Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights
-
Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock
-
Alto Neuroscience Shares Rise After Getting FDA Fast-Track Designation
Trading Information
- Previous Close Price
- $25.31
- Day Range
- $23.87–26.10
- 52-Week Range
- $4.04–37.48
- Bid/Ask
- $22.40 / $27.72
- Shares Outstanding
- 39.24M
- Market Cap
- $973.20M
- Volume/Avg
- 660,690 / 545,769
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 68
- Website
- https://www.altoneuroscience.com
Valuation
|
Metric
|
ANRO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.05 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ANRO
|
|---|---|
Quick Ratio | 14.64 |
Current Ratio | 14.85 |
Interest Coverage | −39.25 |
Quick Ratio
ANRO
Profitability
|
Metric
|
ANRO
|
|---|---|
Return on Assets (Normalized) | −36.08% |
Return on Equity (Normalized) | −43.36% |
Return on Invested Capital (Normalized) | −40.09% |
Return on Assets
ANRO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|>!CM!@ | LOCK|CD!g | $128B | |||
| Moderna Inc
MRNA
| LOCK|h@$NPC | LOCK|^x | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|@Y%>GH | LOCK|?&&p | $76B | |||
| argenx SE ADR
ARGX
| LOCK|n>@C^^@ | LOCK|%pl | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|!S$jbWq | LOCK|#M# | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|%cG@Vk& | LOCK|!T>Y | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|&FYN^@#q | LOCK|@<%Td | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|G&S!Q<> | LOCK|<XN | $24B | |||
| Incyte Corp
INCY
| LOCK|qJ#@?@r | LOCK|h? | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|vLsYHV@ | LOCK|Dw< | $15B |
United States